Metastatic basal cell carcinoma with a high tumor mutational burden that achieved complete response with pembrolizumab

被引：1
|
作者：
Yamakawa, Kohei [1 ]
Ogata, Dai [1 ]
Hiki, Kojiro [1 ]
Jinnai, Shunichi [1 ]
Namikawa, Kenjiro [1 ]
Takahashi, Akira [1 ]
Yamazaki, Naoya [1 ]
机构：
[1] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2023年 / 62卷 / 02期
关键词：
D O I：
10.1111/ijd.16245
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E79 / E80
页数：2
相关论文
共 50 条
  • [31] Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
    Kamei, Jun
    Yokoyama, Hirotaka
    Niki, Toshiro
    Suda, Ryosuke
    Sugihara, Toru
    Fujisaki, Akira
    Ando, Satoshi
    Iwami, Daiki
    Fujimura, Tetsuya
    IJU CASE REPORTS, 2022, 5 (03) : 199 - 202
  • [32] COMPLETE RESPONSE OF METASTATIC BASAL-CELL CARCINOMA TO CISPLATIN CHEMOTHERAPY - A REPORT ON 2 PATIENTS
    KHANDEKAR, JD
    ARCHIVES OF DERMATOLOGY, 1990, 126 (12) : 1660 - 1660
  • [33] Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report
    Chen, San-Chi
    Chao, Yee
    Yang, Muh-Hwa
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (04): : 659 - 660
  • [34] Complete Response to Immunotherapy Combined With Chemotherapy in a Patient With Gynecological Mixed Cancer Mainly Composed of Small Cell Neuroendocrine Carcinoma With High Tumor Mutational Burden: A Case Report
    Su, Xingyun
    Zhou, Xinhui
    Xiao, Cheng
    Peng, Wei
    Wang, Qiangfeng
    Zheng, Yulong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
    Haddad, Robert, I
    Seiwert, Tanguy Y.
    Chow, Laura Q. M.
    Gupta, Shilpa
    Weiss, Jared
    Gluck, Iris
    Eder, Joseph P.
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Kang, Hyunseok
    Muro, Kei
    Albright, Andrew
    Mogg, Robin
    Ayers, Mark
    Huang, Lingkang
    Lunceford, Jared
    Cristescu, Razvan
    Cheng, Jonathan
    Mehra, Ranee
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
  • [36] Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes
    Yamaguchi, K.
    Tsuchihashi, K.
    Ueno, S.
    Uehara, K.
    Taguchi, R.
    Ito, M.
    Isobe, T.
    Imajima, T.
    Kitazono, T.
    Tanoue, K.
    Ohmura, H.
    Akashi, K.
    Baba, E.
    ESMO OPEN, 2025, 10 (01)
  • [37] METASTATIC BASAL-CELL CARCINOMA - RESPONSE TO CHEMOTHERAPY
    BASON, MM
    GRANTKELS, JM
    GOVIL, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 22 (05) : 905 - 908
  • [38] Tumor mutational burden and immune signatures interplay in renal cell carcinoma
    Yakirevich, Evgeny
    Patel, Nimesh R.
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (06)
  • [39] FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors
    Marcus, Leigh
    Fashoyin-Aje, Lola A.
    Donoghue, Martha
    Yuan, Mengdie
    Rodriguez, Lisa
    Gallagher, Pamela S.
    Philip, Reena
    Ghosh, Soma
    Theoret, Marc R.
    Beaver, Julia A.
    Pazdur, Richard
    Lemery, Steven J.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4685 - 4689
  • [40] Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab
    Thiem, Alexander
    Kneitz, Hermann
    Schummer, Patrick
    Herz, Stefan
    Schrama, David
    Houben, Roland
    Goebeler, Matthias
    Schilling, Bastian
    Gesierich, Anja
    ACTA DERMATO-VENEREOLOGICA, 2017, 97 (10) : 1252 - 1254
12345